Scientists Successfully Reprogram Pathogenic T Cells Into Protective Regulatory Cells for Autoimmune Disease Treatment
Key Insights
Two research teams have developed breakthrough cell reprogramming technology that converts disease-causing T cells into protective regulatory T cells (Tregs) for targeted autoimmune disease therapy.
The technology successfully treated pemphigus vulgaris (search) in preclinical models by converting pathogenic Dsg3 (search)-specific T cells into harmless Tregs that migrated to affected areas and reduced blistering without broad immune suppression.
Modified Treg cells also demonstrated efficacy in mouse models of inflammatory bowel disease (search) and graft-versus-host disease (search), suggesting universal applicability across multiple autoimmune conditions.
Two research teams have achieved a significant breakthrough in autoimmune disease treatment by developing cell reprogramming technology that converts pathogenic T cells into protective regulatory T cells (Tregs). The studies, published in Science Translational Medicine, demonstrate successful conversion of disease-causing immune cells into therapeutic agents that could revolutionize treatment approaches for multiple autoimmune conditions.
Targeted Therapy for Pemphigus Vulgaris
In the first study, scientists developed a targeted cell therapy against pemphigus vulgaris (search) (PV), a severe autoimmune skin disease that causes blistering and sores. The researchers isolated Dsg3 (search)-specific pathogenic T cells from both mouse models and human patients, then converted them into harmless Treg cells using specialized chemical tools.
The reprogramming process involved switching on the Foxp3 gene, which controls a cell's ability to help the immune system, while simultaneously cutting off specific activation signals to prevent the cells from reverting to their pathogenic state. When these newly generated Treg cells were injected into a mouse model of PV, they migrated directly to skin-draining lymph nodes and selectively shut down the autoimmune attack, reducing blistering without suppressing other parts of the immune system.
Universal Application Across Inflammatory Conditions
The second study, conducted by members of the same research team including Shimon Sakaguchi—co-author of both papers and winner of the 2025 Nobel Prize in Physiology or Medicine for his discovery of regulatory T cells and immune tolerance—demonstrated the technology's broader applicability. The scientists successfully reprogrammed the most aggressive types of rogue cells that drive various inflammatory conditions.
These modified cells were tested in mouse models of inflammatory bowel disease (search) and graft-versus-host disease (search). Consistent with the pemphigus vulgaris (search) results, the reprogrammed cells migrated to sites of inflammation and effectively suppressed the diseases, demonstrating the technology's potential as a universal tool for converting disease-causing T cells into stable Treg cells.
Advantages Over Current Treatments
This targeted approach represents a significant improvement over traditional immunosuppressant drugs, which can weaken the immune system as a whole. The reprogrammed Treg cells provide selective immune suppression at disease sites while preserving overall immune function, potentially reducing the risk of infections and other complications associated with broad immunosuppression.
"These results suggest that adoptive cell therapy with antigen- or disease-specific S/F-i Treg cells could provide a therapeutic strategy for autoimmune and other inflammatory diseases," the researchers wrote in their study.
Clinical Translation Challenges
While the research offers promising prospects for safer, more targeted treatments for autoimmune diseases, extensive clinical trials will be required to assess the therapy's long-term safety and efficacy in humans. The technology's ability to address autoimmune diseases at their root cause by directly targeting and transforming malfunctioning immune cells could potentially lead to new therapeutic strategies for conditions such as rheumatoid arthritis (search), lupus (search), and multiple sclerosis (search).